4

PRIMARY DOCUMENT

Company: REGENERON PHARMACEUTICALS, INC.
Filed: November 2, 2023
Period of Report: November 1, 2023
Accession Number: 0001883850-23-000079

View Document ↗ View on SEC.gov ↗